Key result
Aspirin provides approximately 25% risk reduction in the secondary prevention of stroke, while nonaspirin compounds are marginally more effective but significantly more expensive.
Why the study?
What are the factors involved in selecting appropriate antiplatelet drugs for secondary prevention of stroke?
What are the factors involved in selecting appropriate antiplatelet drugs for secondary prevention of stroke?
Aspirin remains the standard for secondary stroke prevention, but a targeted 'polypill' approach may offer a better solution than expensive newer agents.
No takes yet. Share an insight, caveat, or question.
John W. Norris (2005) conducted a review in Secondary prevention of stroke. Antiplatelet agents was evaluated. Aspirin provides approximately 25% risk reduction in the secondary prevention of stroke, while nonaspirin compounds are marginally more effective but significantly more expensive.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: